Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., filed a Form 4 on November 13, 2026, disclosing a purchase of 35,000 shares of common stock on November 11, 2026.

Key Highlights

  • Reporting person: Thomas K. Equels, identified in the filing as Director, CEO, and President of AIM ImmunoTech Inc.
  • Transaction: 35,000 shares of common stock acquired (transaction code P) on November 11, 2026.
  • Price paid: $0.149 per share, as reported in the filing.
  • Resulting ownership: 328,095 shares of common stock beneficially owned directly following the transaction.
  • No derivative securities: Table II of the filing contains no reported derivative security transactions.

Equels Purchases AIM ImmunoTech Common Stock on November 11, 2026

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Thomas K. Equels, who serves as both a Director and as CEO and President of AIM ImmunoTech Inc. (listed on the filing as ticker AIM), purchased 35,000 shares of the company's common stock on November 11, 2026. The filing records the transaction under code P, indicating an open-market purchase, at a price of $0.149 per share.

Following the reported transaction, the filing states that Equels beneficially owns 328,095 shares of AIM ImmunoTech common stock directly. The form was signed by Thomas K. Equels and filed on November 13, 2026. No deemed execution date was indicated for the transaction, and the filing was submitted as an individual report by one reporting person.

Table II of the filing, covering derivative securities such as puts, calls, warrants, options, or convertible securities, reflects no transactions. The filing lists Equels's address as 2117 Southwest Highway 484, Ocala, Florida 34473.

What Was Disclosed

The filing disclosed a direct open-market purchase of 35,000 shares of AIM ImmunoTech Inc. common stock by CEO and President Thomas K. Equels at $0.149 per share on November 11, 2026, bringing his total direct beneficial ownership to 328,095 shares.